beyond Oregon

BERLIN – June 28, 2012 -- Now that the Supreme Court has upheld President Obama’s healthcare plan, pharmaceutical companies, patients and healthcare experts in Europe are waiting to see how a new cost reducing drug price mechanism affects them.Requiring citizens to have healthcare has long been a staple of European health insurance programs. But now governments and insurers are trying to stem the cost of exorbitantly expensive new drugs.